Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

The maximum days the report can be obtained for the test FIP1L1-PDGFRA Gene Rearrangement Test By PCR is 7 days.

What are the prerequisites for the test FIP1L1-PDGFRA Gene Rearrangement Test By PCR

Prerequisites for FIP1L1-PDGFRA Gene Rearrangement Test By PCR:

  • Specimen: Blood or bone marrow sample
  • Sample should be collected in an EDTA tube
  • Properly labelled sample with patient details
  • Requisition form with appropriate clinical information
  • Written consent from the patient for the test
  • Proper transportation of the sample to the laboratory

What are the measure values for the test FIP1L1-PDGFRA Gene Rearrangement Test By PCR

  • Positive: FIP1L1-PDGFRA gene rearrangement detected
  • Negative: FIP1L1-PDGFRA gene rearrangement not detected
  • Indeterminate: Inconclusive result, further testing may be required

What does this test FIP1L1-PDGFRA Gene Rearrangement Test By PCR identify?

  • This test identifies the presence of a fusion gene known as FIP1L1-PDGFRA by using a technique called PCR (Polymerase Chain Reaction).
  • The FIP1L1-PDGFRA gene rearrangement is associated with a rare subtype of a myeloproliferative neoplasm called chronic eosinophilic leukemia (CEL).
  • Identification of this gene rearrangement is important for diagnosis and treatment planning in patients with suspected CEL.
  • PCR is a highly sensitive and specific method for detecting specific genetic alterations like the FIP1L1-PDGFRA fusion gene.

Why is this test FIP1L1-PDGFRA Gene Rearrangement Test By PCR taken?

The FIP1L1-PDGFRA gene rearrangement test is taken to detect a specific genetic abnormality that is associated with a rare form of leukemia known as hypereosinophilic syndrome (HES). This abnormality involves a fusion of the FIP1L1 gene with the PDGFRA gene, leading to uncontrolled cell growth and proliferation.

Testing for the FIP1L1-PDGFRA gene rearrangement is important in diagnosing and monitoring HES, as it can help guide treatment decisions. Targeted therapies, such as tyrosine kinase inhibitors, have been developed to specifically target the abnormal protein produced by this gene fusion, leading to better outcomes for patients with HES.

No FAQs available.

Customer Google Rating